Immune Pharmaceuticals Enters a Research Partnership to Develop Mono- and Bispecific Antibodies Against Novel Targets in the Tumor Microenvironment

NEW YORK, Jan. 23, 2017 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP), “Immune”, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of immuno-inflammatory diseases and cancers, announced today that it has entered an exclusive sub-license agreement with SATT Sud-Est, a French Technology Transfer Office, to develop, use, manufacture and commercialize mono- and bispecific antibodies…